HRS9531
Hengrui’s HRS9531 NDA Accepted in China, First Homegrown GLP-1/GIP Dual Agonist to Challenge Tirzepatide
Hengrui’s HRS9531 NDA is accepted in China, marking the first homegrown GLP-1/GIP dual agonist for obesity. Clinical data shows strong weight loss and safety, challenging Eli Lilly’s tirzepatide in China’s fast-growing market.